Anthem Biosciences IPO Opens July 14: Key Details, Strengths, and Risks

Contract research and manufacturing company Anthem Biosciences is launching its Initial Public Offering (IPO) on Monday, July 14, 2025. The issue is entirely an Offer for Sale (OFS), where promoters and existing investors will sell up to 59.6 million shares, amounting to ₹3,395 crore.

Anthem Biosciences IPO Price and Date

• Price Band: ₹540–₹570 per share
• Minimum Application: 26 shares per lot
• Issue Dates: July 14 to July 16, 2025
• Listing Date (Tentative): July 21, 2025

Anthem Biosciences will not receive any money from the IPO, as all funds will go to the selling shareholders.

Key Strengths of Anthem Biosciences IPO

1. Global Customer Base: As of March 2025, the company had over 550 clients across 44 countries, including the US, Europe, and Japan.
2. Industry-Leading Fermentation Capacity: Anthem has the highest fermentation capacity among Indian CRDMO companies at 142 kL, expected to reach 182 kL by mid-FY26.
3. Strong Speciality Ingredients Portfolio: The company produces niche products like GLP-1, probiotics, enzymes, vitamins, and biosimilars, addressing rising demand.
4. Focus on Emerging Pharma and Biotech Players: Anthem supports small and innovative pharma firms throughout the drug development cycle—from research to manufacturing.
5. End-to-End Services: It offers a one-stop solution for both small molecules and biologics, making it the fastest-growing CRDMO in India.

Risks to Consider in Anthem Biosciences IPO

1. Heavy Dependence on CRDMO: CRDMO services make up over 81% of its revenue. Any downturn in client business may hit earnings.
2. Reliance on DavosPharma (US Market): The US business is dependent on one key partner—DavosPharma, which also plans to sell its stake.
3. Dependence on Specific Molecules: Failures in drug development, like the Phase III trial setback, have previously impacted revenue.
4. Risk of Project Failures: Over 70% of revenue comes from project-based work, which may face uncertainty or fail.
5. Regulatory Challenges: The company must comply with multiple government approvals and licenses, exposing it to compliance risks.

Read more: Dividend Stocks: Dr Reddy's, LMW, Wheels India, Diffusion Engineers Trade Ex-Dividend Today.

Conclusion

Anthem Biosciences’ IPO offers investors a chance to tap into a fast-growing pharma services company with a global footprint. While its strong customer base and service offerings are impressive, investors should be mindful of its high dependency on specific services, partners, and molecules. As always, detailed due diligence is key before investing.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.